Xvivo Perfusion AB (publ)
XVIPY · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $9 | $10 | $15 | $16 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $9 | $10 | $15 | $16 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -18.4% | -3.9% | 14.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 74.4% | 73.4% | 77% | 74.5% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 9% | 17.3% | 12.3% | 10.3% |
| Net Income | $0 | -$0 | $0 | $0 |
| % Margin | 0.9% | -5.7% | 16% | 43.2% |
| EPS Diluted | 0.013 | -0.098 | 0.29 | 0.68 |
| % Growth | 112.8% | -133.6% | -57.4% | – |
| Operating Cash Flow | $0 | -$0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | $0 | $0 |